Rocket Pharmaceuticals, RP-A501, Danon Disease, Gene Therapy, Phase 2 Clinical Trial, FDA, LAMP2B, AAV9, Inherited Cardiovascular Disease, Hypertrophic Cardiomyopathy,

CRANBURY, N.J. — October 7, 2026 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) outlined development milestones and updated clinical findings for...